Abstract

Title : THE PREVALENCE OF OVERWEIGHT AND OBESITY IN PSYCHIATRIC PATIENTS RECEIVED ANTIPSYCHOTICS AT PRASRIMAHABHODI PSYCHIATRIC HOSPITALS, UBONRATCHATHANI
By : KHANITTA SUTORN MUNGKORN CHAIWATTANA NUNGRUTHAI TANGWIGRAI
Degree : BACHELOR OF PHARMACY
Advisor : TATTA SRIBOONRUANG SUTTASINEE SUWANNAKUL
Keywords : Overweight , Obesity , Clozapine , Risperidone , Body mass index
   
Objective = The purposes of this study were to determine the prevalence of overweight and obesity in psychiatric female patients received clozapine, risperidone, and combination of clozapine and risperidone and to explore the factors associated with overweight and obesity among these patients. Methods = A cross-sectional study was performed in 57 females patients aged 18-59 years old at inpatient department of Prasrimahabhodi Psychiatric hospital in December 2011. Subjects were divided into 3 groups according to their antipsychotics treatment= clozapine, risperidone, combination of clozapine and risperidone. Data (such as demographic data, weight, height, body mass index (BMI), waist and hip circumference) and factors (such as religion, nationality, marital status, occupation, education dose, duration, co-diseases, co-medications) were collected from patients and medical chart. The assessment of overweight and obesity follow the standard criterion for Asian population. The descriptive statistics , Chi-square test and analysis of variance (ANOVA) were used in the analysis of data and association of factors. Results = Out of 3 groups of subject (41 subjects on clozapine, 11 subjects on risperidone, and 5 subjects on combination therapy), it was found that only patients in clozapine group presented overweight 5 (12.19%) and obesity 1 (2.44%). The mean BMI in each groups were 22.10 , 20.99 and 21.49 kg/m2 respectively. However, the average BMI after start antipsychotics were increased in all 3 groups as shown 0.53, 0.52 and 0.87 in groups of clozapine, risperidone, clozapine plus risperidone; respectively. The associations of factors were not found in this study. In addition, there are not significantly different in mean of BMI, BMI change, weight, waist, hip, arm circumferences between three groups. Conclusion and discussion = Higher prevalence of overweight and obesity in clozapine group compare to the others. The results correlate with the previous studies that clozapine induced recurrence or deterioration of binge eating-related eating disorders resulting in weight gain because increase appetite. This research has been shown the current weight situation in antipsychotics use as shown as the prevalence of overweight and obesity.
   
Close this window